Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China.
PLoS One 2019; 14(12):e0224580Plos

Abstract

The use of aspirin for primary prevention of cardiovascular disease (CVD) in patients with diabetes mellitus (DM) is associated with lower rates of cardiovascular events but increased risks of bleeding complications. We aimed to examine the cost-effectiveness of aspirin therapy for primary prevention of CVD in Chinese DM patients. A life-long Markov model was developed to compare aspirin therapy (100mg daily) versus no use of aspirin in DM patients with no history of CVD. Model validation was conducted by comparing the simulated event rates with data reported in a clinical trial. Direct medical costs and quality-adjusted life-years gained (QALYs) were the primary outcomes from the perspective of healthcare system in China. Sensitivity analyses were performed to examine the uncertainty of model inputs. Base-case analysis showed aspirin therapy was more costly (USD1,086 versus USD819) with higher QALYs gained (11.94 versus 11.86 QALYs) compared to no use of aspirin. The base-case results were sensitive to the odds ratio of all-cause death in aspirin therapy versus no use of aspirin. Probabilistic sensitivity analysis found that aspirin therapy gained an additional 0.066 QALYs (95% CI: -0.167 QALYs-0.286 QALYs) at higher cost by USD352 (95% CI: USD130-644)). Using 30,000 USD/QALY as willingness-to-pay threshold, aspirin therapy and no use of aspirin were the preferred option in 68.71% and 31.29% of 10,000 Monte Carlo simulations, respectively. In conclusion, aspirin therapy appears to be cost-effective compared with no use of aspirin in primary prevention of CVD in Chinese DM patients.

Authors+Show Affiliations

Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China. Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, China.Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China. Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, China.School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T, Hong Kong, China SAR.Department of Cardiovascular Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.Department of Cardiovascular Medicine, Shaanxi Provincial People's Hospital, Xi'an, China.Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China. Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, China.Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China. Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31790409

Citation

Jiang, Minghuan, et al. "Cost-effectiveness Analysis of Aspirin for Primary Prevention of Cardiovascular Events Among Patients With Type 2 Diabetes in China." PloS One, vol. 14, no. 12, 2019, pp. e0224580.
Jiang M, Li P, You JH, et al. Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China. PLoS ONE. 2019;14(12):e0224580.
Jiang, M., Li, P., You, J. H., Zheng, X., Deng, J., Zhao, M., ... Fang, Y. (2019). Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China. PloS One, 14(12), pp. e0224580. doi:10.1371/journal.pone.0224580.
Jiang M, et al. Cost-effectiveness Analysis of Aspirin for Primary Prevention of Cardiovascular Events Among Patients With Type 2 Diabetes in China. PLoS ONE. 2019;14(12):e0224580. PubMed PMID: 31790409.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China. AU - Jiang,Minghuan, AU - Li,Pengchao, AU - You,Joyce Hoi-Sze, AU - Zheng,Xinglong, AU - Deng,Jizhao, AU - Zhao,Mingyue, AU - Feng,Liuxin, AU - Fang,Yu, Y1 - 2019/12/02/ PY - 2019/05/29/received PY - 2019/10/16/accepted PY - 2019/12/3/entrez PY - 2019/12/4/pubmed PY - 2019/12/4/medline SP - e0224580 EP - e0224580 JF - PloS one JO - PLoS ONE VL - 14 IS - 12 N2 - The use of aspirin for primary prevention of cardiovascular disease (CVD) in patients with diabetes mellitus (DM) is associated with lower rates of cardiovascular events but increased risks of bleeding complications. We aimed to examine the cost-effectiveness of aspirin therapy for primary prevention of CVD in Chinese DM patients. A life-long Markov model was developed to compare aspirin therapy (100mg daily) versus no use of aspirin in DM patients with no history of CVD. Model validation was conducted by comparing the simulated event rates with data reported in a clinical trial. Direct medical costs and quality-adjusted life-years gained (QALYs) were the primary outcomes from the perspective of healthcare system in China. Sensitivity analyses were performed to examine the uncertainty of model inputs. Base-case analysis showed aspirin therapy was more costly (USD1,086 versus USD819) with higher QALYs gained (11.94 versus 11.86 QALYs) compared to no use of aspirin. The base-case results were sensitive to the odds ratio of all-cause death in aspirin therapy versus no use of aspirin. Probabilistic sensitivity analysis found that aspirin therapy gained an additional 0.066 QALYs (95% CI: -0.167 QALYs-0.286 QALYs) at higher cost by USD352 (95% CI: USD130-644)). Using 30,000 USD/QALY as willingness-to-pay threshold, aspirin therapy and no use of aspirin were the preferred option in 68.71% and 31.29% of 10,000 Monte Carlo simulations, respectively. In conclusion, aspirin therapy appears to be cost-effective compared with no use of aspirin in primary prevention of CVD in Chinese DM patients. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/31790409/Cost-effectiveness_analysis_of_aspirin_for_primary_prevention_of_cardiovascular_events_among_patients_with_type_2_diabetes_in_China L2 - http://dx.plos.org/10.1371/journal.pone.0224580 DB - PRIME DP - Unbound Medicine ER -